Revenue Insights: Biogen Inc. and Jazz Pharmaceuticals plc Performance Compared

Biogen vs. Jazz: A Decade of Revenue Dynamics

__timestampBiogen Inc.Jazz Pharmaceuticals plc
Wednesday, January 1, 201497033240001172875000
Thursday, January 1, 2015107638000001324803000
Friday, January 1, 2016114488000001487973000
Sunday, January 1, 2017122739000001618693000
Monday, January 1, 2018134529000001890922000
Tuesday, January 1, 2019143779000002161761000
Wednesday, January 1, 2020134446000002363567000
Friday, January 1, 2021109817000003094238000
Saturday, January 1, 2022101734000003659374000
Sunday, January 1, 202398356000003834204000
Monday, January 1, 20249675900000
Loading chart...

Data in motion

Revenue Growth: Biogen Inc. vs. Jazz Pharmaceuticals plc

In the competitive landscape of the pharmaceutical industry, revenue growth is a key indicator of success. From 2014 to 2023, Biogen Inc. and Jazz Pharmaceuticals plc have shown distinct revenue trajectories. Biogen Inc., a leader in biotechnology, saw its revenue peak in 2019, reaching approximately 14.4 billion USD, before experiencing a gradual decline to around 9.8 billion USD by 2023. This represents a decrease of about 32% over four years, highlighting challenges in maintaining its market dominance.

Conversely, Jazz Pharmaceuticals plc, known for its innovative therapies, demonstrated a robust growth pattern. Starting at 1.2 billion USD in 2014, Jazz's revenue surged to nearly 3.8 billion USD by 2023, marking an impressive growth of over 220%. This stark contrast underscores Jazz's strategic advancements and market expansion, positioning it as a formidable player in the pharmaceutical sector.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025